Children with obesity and specific comorbidities, including hypertension and type 2 diabetes, have increased risk for almost every skin condition.

University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...

Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now ...

The administration is reviewing a Centers for Medicare and Medicaid Services rule that would expand coverage to Medicare and Medicaid recipients ...

No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...

Fortunately, with President Trump’s leadership on the issue, he can turn the tide in the quest to end obesity. There’s a ...

Eli Lilly India launches Mounjaro, a first-of-its-kind medication for obesity and type 2 diabetes, offering hope for millions ...

Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with we ...

The researchers observed an association between childhood obesity and increased rates of all dermatologic conditions and the associated comorbidities evaluated. The most commonly associated ...

The company said it has introduced Mounjaro in a single-dose vial presentation following the marketing authorisation from the ...